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Background: There is little understanding of the mechanisms that explain why testicular germ cell tumors respond so well
to chemotherapy.
Results:Noxa is transcriptionally activated byKLF6 andTAp73 and repressed by Sp1 andNp73, and its protein levels correlate
with clinical prognosis.
Conclusion: p73 isoforms and Sp1-like factors form a cisplatin-induced transcriptional network that regulate proapoptotic
Noxa.
Significance: This might help understand the transcriptional pathways of chemosensitivity.
Testicular germ cell tumors (TGCTs) are highly responsive to
and curable by cisplatin-based chemotherapy even in advanced
stages. We have studied the molecular mechanisms involved in
the induction of apoptosis in response to cisplatin, and found
that proapoptoticNoxa is transcriptionally up-regulated follow-
ing cisplatin exposure, even in the absence of p53, in NTERA2
cisplatin-sensitive cells but not in 1411HP-resistant cells.
Blockade of Noxa reduced the apoptotic response of embryonal
carcinoma (EC)NTERA2 cells to cisplatin. A detailed analysis of
the Noxa promoter revealed that p73 and Sp1-like factors, Sp1
and KLF6, played key roles in the transcriptional control of this
gene. Overexpression of TAp73 induced Noxa whereas the
dominant negative isoform Np73, reduced the levels of Noxa
after cisplatin exposure in NTERA2 and 2102EP. Interestingly,
down-regulation of Sp1 increased Noxa expression in response
to cisplatin. However, blockade of KLF6 decreased cisplatin-in-
duced up-regulation of Noxa in EC cell lines. In addition, tissue
microarray analyses of TGCTs revealed that expression of
Noxa correlates with good clinical prognosis in patients with
embryonal carcinoma. Thus, our data show the transcrip-
tional network that regulates Noxa in EC cells, which is key
for their apoptotic response to cisplatin-based chemother-
apy, and propose Noxa as a predictive factor of therapeutic
response.
Although conventional chemotherapy is often regarded as a
sub-optimal treatment strategy, with high toxicity and less than
curative outcomes in common adult cancers, there are several
well documented situations, such as germ-line or pediatric can-
cers in which these therapies can provide complete cures (1).
For example, cisplatin cures most patients with advanced tes-
ticular cancer and has been the standard treatment for decades
(2, 3). Perhaps because it has been so successful, few studies of
this drug response are being conducted. Yet, knowing why this
drug and others can produce such efficient cures could illumi-
nate the search for similar opportunities for cancers that are
less successfully treated.
Cisplatin is an antineoplastic in the class of alkylating agents
that has been shown to induce apoptotic cell death (4). Apopto-
sis is a tightly regulated and highly efficient cell death system
that requires specialized molecular machinery. A key compo-
nent of this machinery is the Bcl-2 family of apoptosis regula-
tors. Whether a cell dies in response to diverse apoptotic stim-
uli, including DNA-damaging agents, is determined largely by
interactions between antiapoptotic (Bcl-2-like) and proapo-
totic (BH3-only and Bax-like) members of this family (5). A
death signal is transmitted through the BH3-only proteins to
Bax and Bak which in turn permeabilize the outer mitochon-
drial membrane allowing the release of apoptogenic factors (6).
The tumor suppressor p53 is one of the main transcription
factors involved in the regulation of proapoptotic Bcl-2 family
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members. This protein plays a pivotal role in the decision of
whether the outcome of DNA damage will be growth arrest or
apoptosis, and this choice is mainly based on its transcriptional
activity. Among the BH3-only genes, puma, noxa, and bik have
been shown to be induced by the p53 pathway (7–9).Noxa plays
a main role in fine-tuning cell death decisions by targeting the
prosurvival molecule Mcl-1 for proteasomal degradation. This
event appears to be critical for cell death induction in response
to factor deprivation or DNA damage (10). Besides p53, Noxa
has been shown to be induced by other transcription factors,
including HIF1, E2F1 and p73 (11–13). Although hypoxia-
induced expression of Puma is mainly dependent on p53, Noxa
has been described as a direct target of HIF1, and mediates
hypoxic cell death in a p53-independentmanner in various nor-
mal and malignant tissues. Ectopic expression of E2F1 can also
trigger apoptosis through direct binding to a consensus E2F1-
binding site in the Noxa promoter. In addition, p73 is able to
bind to p53 consensus sites, and it promotes the expression of
Noxa in different tumor cells (13, 14). Although p53 has been
proposed as a mediator of the sensitivity of testicular germ cell
tumor (TGCT)2 cells to cisplatin, high levels of p53 does not
correlate directly to treatment sensitivity of these tumors, and
inactivation of p53 is not a common event in the development
of cisplatin resistance (15, 16). Moreover, a subgroup of TGCT
patients with embryonal carcinoma and a tumor profile with
low p53, showed better survival than that of the overall TGCT
patient group (17). These observations support a multifactorial
basis for the chemosensitivity of TGCTs (18). Cisplatin has
been shown to induce Noxa expression in a number of cell
systems including ovarian cancer, neuroectodermal tumors,
andTGCTs (19–21), which strongly correlates with an apopto-
tic response of cancer cells. However, the transcriptionalmech-
anisms involved in the cisplatin-dependent regulation of this
proapoptotic gene are still controversial. Here, we have used
TGCT cell lines to demonstrate that the key role that Noxa
plays in transducing the apoptotic response to cisplatin is con-
trolled by a balance between transcriptional activation medi-
ated by p73 and KLF6 and repression by Sp1. Moreover, by
using immunohistochemistry on tissue microarrays, we show
for the first time that the expression of Noxa correlates with
clinical prognosis in embryonal carcinoma patients.
EXPERIMENTAL PROCEDURES
Cell Lines—The germ cell tumor cell lines with an embryonal
carcinoma phenotype, 2102Ep, TERA1, and NTERA2, a yolk
sac carcinoma line, 1411HP, and amalignant teratoma cell line,
577MF, were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal calf serum (Flow Laboratories, Irvine, CA). Dro-
sophila Schneider SL-2 cells were grown in Shield and Sang
DES (Drosophila-enriched Schneider) insect medium (Sigma-
Aldrich) supplemented with 10% fetal calf serum.
Western Blot Analysis and Immunoprecipitation—Cell
extracts (50 g of protein) were separated on a 8% polyacryl-
amide gel, and transferred to nitrocellulose. Blots were blocked
with 3% BSA and incubated with rabbit antibodies against
KLF6, Sp1, Mcl-1, PARP, p53, and p73 (all from Santa Cruz
Biotechnology, Santa Cruz, CA), or mouse monoclonal anti-
bodies against Noxa (Millipore), Bad (BD Biosciences, San
Diego, CA) and Tubulin, (Santa Cruz Biotechnology), fol-
lowed by incubation with goat anti-rabbit or anti-mouse anti-
bodies conjugated to alkaline phospatase (Sigma-Aldrich).
Bound antibody was detected by a chemiluminescence system
(Applied Biosystems, Foster City, CA). For protein immuno-
precipitation, NTERA2 cells were lysed in 0.5% Nonidet P-40-
containing solution as previously described (22). Cleared
lysates were incubated with rabbit anti-Mcl-1 antibodies, and
protein A/G conjugated to agarose beads (Santa Cruz Biotech-
nology). Proteins eluted from the agarose beads were electro-
phoresed and transferred to nitrocellulose. Membranes were
incubated with the indicated antibodies.
Chromatin Immunoprecipitation (ChIP)—Purification of
sonicated nuclear lysates and immunoprecipitation were per-
formed as described elsewhere (23). Precipitates using anti-Sp1,
anti-KLF6, anti-p73 (Santa Cruz Biotechnology), or irrelevant
IgG were heated at 65 °C for at least 4 h to reverse the formal-
dehyde cross-linking. Proteins were digested in the presence of
20 g/l Proteinase K, and then DNA fragments were purified
with a QIAquick Spin Kit (Qiagen, Valencia, CA). Quantitative
PCR was performed using primers 5-ACGTCCAGCGTTTG-
CAGATG-3 and 5-GACGTAGGGAAACTAGACGCC-3
that generate a 258-bp fragment containing the Sp1 and p53
sites, and primers 5-GGGATTACAGGCGTGAGAGA-3 and
5-GTGCTGTAGATCGATTGTGTTTG-3 that generate a
127-bp fragment, 3 kb further upstream, used as a negative
control of immunoprecipitation.
Electrophoretic Mobility Shift Assay (EMSA)—Cells were
lysed and nuclear fractions were resuspended in 20 mMHEPES
pH 7.9, 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 20%
glycerol. Nuclear extracts (10 g of total protein) were incu-
bated with a 32P-labeled double stranded DNA probe corre-
sponding to a sequence from theNoxa promoter that contained
the Sp1 binding site (5-GCGGGGCGGGGACAGGGGCG-
GGGACAGGGGCGGGCC-3). Samples were run on a 5%
non-denaturing polyacrylamide gel in 200 mM Tris borate, 2
mM EDTA. Gels were dried and visualized by autoradiography.
Supershifts were performed using antibodies against Sp1 and
GATA1 (used here as an irrelevant antibody) (both from Santa
Cruz Biotechnology).
Analyses of mRNA Expression—Total RNA from germ cell
tumor cell lines was extracted using the RNeasy mini kit
(Qiagen). To assess the expression of individual genes, a cDNA
was generated and amplified by using primers for human noxa
(5-ATGCTGCGTTTCACCAGGG-3) and (5-TCCATG-
CTACTTGCACTTGTTCCT-3), bim (5-CCAGCACCCAT-
GAGTTGTGAC-3, and 5-TGGTCTTCGTGCTGCTTGG-
3), and -actin (5-GCGGGAAATCGTGCGTGACATT-3,
and 5-GATGGAGTTGAAGGTAGTTTCGTG-3). Quanti-
tative real-time PCR was performed in a 7000 Sequence Detec-
tion System (Applied Biosystems).
Cell Viability Assays—Viability in response to cisplatin was
analyzed by using the WST-1 reagent (Roche Applied Science,
Indianapolis, IN) that is cleaved to formazan dye by mitochon-
2 The abbreviations used are: TGCT, testicular germ cell tumor; EC, embryonal
carcinoma; KLF, Kruppel-like factor.
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drial dehydrogenases, which directly correlates to the number
of metabolically active cells in the culture. Apoptosis was
determined with a DeadEnd fluorometric TUNEL system
(Promega Corp., Madison, WI) following the manufacturer’s
recommendations.
Transfection Experiments and Gene Reporter Assays—A
genomic PCR fragment from the promoter region of Noxa,
containing the sequence from1292 to85 bp relative to the
transcription start site, was cloned into KpnI and XhoI sites of
the pGL2-basic luciferase reporter vector (Promega). The
authenticity of the construct was confirmed by sequencing.
Serial deletions were obtained by digestion with NsiI (cuts at
position892), StuI (cuts at position423) or by PCRwith the
following primers that contained a KpnI sequence at the 5 end,
5-GAGGTACCAAGTAATTTCGGGGCCGAGC-3 (for a
fragment starting at 256), 5-GAGGTACCTCGCTGCT-
CAGCGGGGTACTT-3 (for a fragment starting at 177),
5-GAGGTACCTCCTGCTCCCATAACGCCGTCT-3 (for a
fragment starting at 139), 5-GAGGTACCTAGTTTC-
CCTACGTCACCAG-3 (for a fragment starting at 75),
5-GAGGTACCCTGGACAAAAGCGTGGTCTC-3 (for a
fragment starting at 44). In all PCRs, the same antisense
primer (5-GACTCGAGTGAACACGAACAGTCCTGCA-3)
with a XhoI site at the 5-end was used. Cell lines were co-
transfected with 1 g of pGL2 vector containing the different
promoter fragments and 50 ng of pRSV--gal by lipofection
using Superfect (Qiagen). When indicated, cells were co-trans-
fected with 1 g of pGL2-Noxa-promoter and 1 g of expres-
sion plasmids containing TAp73, Np73 (24), KLF6, or KLF6
Sv2 (25). 24 h post-transfection, cell extracts were prepared and
analyzed for the relative luciferase activity by a dual-light
reporter gene assay system (Applied Biosystems). Results were
normalized for transfection efficiency with values obtained
with pRSV--gal. Site-directed mutagenesis was carried out by
using the QuickChange Site-directed mutagenesis kit (Strat-
agene, La Jolla, CA) with the following primers to mutate Egr1
(5-CCGAGCTGCTCTGCTCCAAACGCCGCGGGTCG-3),
p53 (5-CGCCGCGGGTCGGTGCTAGGGTCCGGGCAG-
GTCG-3) and Sp1 (5-CGGGATGGGGACAGGGATGG-
GGACAGGGATGGGCCGGG-3) sites (changes are under-
lined). In all cases, DNA inserts were sequenced to verify the
mutation.
Gene Silencing—Cells were cultured at a density of 1  106
cells/ml and transfected with shRNA plasmids specific for
Noxa, p53 and Sp1, or control scrambled shRNA containing
plasmid (MISSION shRNA library, Sigma-Aldrich) using Lipo-
fectamine or nucleofection (Amaxa, Cologne, Germany) for
24 h.
Prognostic Groups of Patients—A retrospective cohort of 75
consecutive male patients with metastatic germ cell tumors
treated at the Catalan Institute of Oncology from August 1989
to November 2004 were included in this study. Clinical prog-
nosis was classified according to the International Germ Cell
Cancer Collaborative Group (26) as good prognosis (60%),
defined by complete or partial response by imaging procedures
(computed tomography-scan) and negative serum tumor
markers; bad prognosis (21%), defined by partial response or
stabilization of disease and positive tumor markers (this group
includes 41.6% of resistant cases); and intermediate prognosis
(19%). All patients were treated with cisplatin-based chemo-
therapy following the Spanish Germ Cell Group protocol, and
they were considered resistant when progression or relapse
occurred despite adequate initial treatment.
Tissue Microarray—Formalin-fixed paraffin-embedded tis-
sue samples of representative tumor regions from primary
tumors and/or resected metastasis were collected for the prep-
aration of eight tissue microarrays. Briefly, three tissue cylin-
ders with a diameter of 1.0 mm were punched from morpho-
logically representative areas of each donor tissue block and
brought into a recipient paraffin block using a manual tissue
arrayer. For mixed tumors, three cylinders of each component
were included.
Immunohistochemistry and Scoring—Paraffin-embeded sec-
tions were deparaffinized in xylene and rehydrated in down-
graded alcohols and distilled water. Then, tissue microarrays
were incubated with anti-Noxa antibodies (OP180, Millipore),
followed by a specific secondary antibody using the DAB Map
detection kit (VentanaMedical Systems, Tucson, AR). Sections
were counterstained with hematoxylin and analyzed by light
microscopy. For immunoreactivity, a previously reported 0–3
semi-quantitative scoring system for both the intensity of stain
and the percentage of positive cells (labeling frequency percent-
age) was used (27). For intensity of stain, each case was visually
compared with both positive and negative controls. The grad-
ing scale ranged from no detectable signal (0 points), to strong
signal seen at low power (3 points). Labeling frequency was
scored as 0 (0%), 1 (1 to 33%), 2 (34 to 66%), or 3 (67–100%). The
multiplicative index of intensity and labeling was considered
for analysis. Each image was interpreted by three independent
observers (T.H., S.F., and E.de A.).
Statistical Analysis—All statistics were calculated with the
SPSS statistical package (version 13.0). The Student’s t test was
used to compare continuous variables between two groups. The
significance level was set at p 0.05.
RESULTS
Noxa Expression and Resistance to Cisplatin in Germ Cell
Tumor Cell Lines—We first studied the expression levels of
Noxa in TGCT cell lines. As shown in Fig. 1A, 577ML4,
NTERA2, TERA1, and 2102Ep cells expressed the Noxa pro-
tein, although the levels varied significantly between the differ-
ent cell lines. Interestingly, 1411HP cells which are known to be
resistant to cisplatin (28) expressed the lowest levels of Noxa.
This expression pattern was also evident at the level of mRNA
(Fig. 1B) suggesting a correlation between the transcriptional
control of this proapoptotic gene and the cellular response to
cisplatin. Another BH3-only gene, Bim, did not show expres-
sion differences in 1411HP cells with respect to other cell lines
(Fig. 1B). The best known function of Noxa is to bind to and
neutralize the antiapoptotic activity of Mcl-1. We verified the
presence of this protein complex in our cell system by immu-
noprecipitation experiments. An antibody against Mcl-1 was
able to co-immunoprecipitate Noxa, but not the BH3-only pro-
tein Bad (Fig. 1C). Of note, the Mcl-1 protein was absent or
expressed at very low levels in 1411HP cell line (Fig. 1A). Next,
we determined whether the expression of Noxa correlated with
p73 and Sp1-like Factors Control Noxa in EC Cells
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the apoptotic response of cells to cisplatin. A TUNEL assay
showed that the proportion of apoptotic cells was higher than
50% in both NTERA2 and 2102Ep cell lines but less than 9% in
1411HP after 24h of treatment with cisplatin (Fig. 2A). This
result was confirmed by analyzing the digestion of PARP, a
substrate of caspases. Following cisplatin exposure, the cleav-
age product of PARP was readily detected in NTERA2 and
2102Ep cell lines. However, only a small proportion of PARP
was digested even after 48 h of incubation of 1411HP cells in the
presence of cisplatin (Fig. 2B). These data correlated with the
induction (about 3-fold) of Noxa in NTERA2 cells in response
to cisplatin, in contrast to the low levels of Noxa protein in
treated 1411HP cells, which were even lower than those in
untreated NTERA2 (Fig. 2C). In order to verify that the expres-
sion of Noxa in response to cisplatin was transcriptionally reg-
ulated, NTERA2 and 1411HP cells were transfected with a
luciferase reporter driven by the noxa promoter and then
treated with cisplatin. After 3 h of exposure to the chemother-
apeutic drug, the luciferase activity increased about 10 times in
NTERA2 (Fig. 2D). However, no variations were observed in
1411HP under the same experimental conditions.
Down-regulation ofNoxaReverts Resistance to Cisplatin—To
determine the functional relevance of Noxa in the apoptotic
response of TGCT cells to cisplatin, we blocked the expression
of Noxa inNTERA2 cells by an interference RNA strategy. Two
out of five Noxa-targeted shRNAs promoted a significant
reduction of Noxa protein levels. One of these, sh2-Noxa,
almost abrogated the expression of the BH3-only protein (Fig.
3A). Cells transfected with sh2-Noxa were more resistant
(about two times more viable cells) to cisplatin than control
transfected cells, reducing the cell viability to almost 20% (Fig.
3B). Similar but less pronounced effects in cell viability were
observed when cells were transfected with sh3-Noxa, and no
significant difference with respect to controls were detected in
cells transfectedwith the other three shRNAs (data not shown).
These results indicate thatNoxa contributes to the sensitivity of
TGCT cells to cisplatin and provides a molecular rationale to
explain the good therapeutic response of testicular germ cell
tumors.
Analysis of Regulatory Elements in the Noxa Promoter—
Based on our previous findings, we looked for transcription
factor binding sites in the noxa promoter that were functional
in TGCT cells. We found consensus binding sequences for
HIF1, p53, Egr1, Sp1, and E2F1 transcription factors within
1.3 kb upstream from the transcription start site (Fig. 4A).
Restriction fragments of the promoter were sequentially
obtained and cloned into a luciferase reporter construct. Lucif-
erase assays demonstrated that the promoter activity was
located in a fragment of 423 bp that contained Egr1, p53, Sp1,
and E2F1 sites (Fig. 4B). Loss of a sequence from423 to177
caused a 5-fold reduction in luciferase activity indicating the
relevance of Egr1 and/or p53 sites to the expression of Noxa in
NTERA2 cells. Further deletion to position 75 which elimi-
nated the Sp1 site but maintained the E2F1 sequence, com-
pletely abrogated the activity of the promoter. To further nar-
row down the sequence containing the active binding sites,
PCR fragments from positions256 and139 were generated
and the corresponding luciferase reporter constructs were
transfected into NTERA2 and 2102Ep cells. The biggest frag-
ment retained the activity of the original 1.3 kb promoter
sequence, and this activity was drastically reduced when the
promoter contained a deletion up to position 139 (Fig. 4C).
Again, luciferase activity was abolished in both cell lines trans-
fectedwith a construct containing the first 75 nucleotides of the
promoter. These data confirmed that Egr1 and/or p53, and Sp1
siteswere important for the activity ofNoxa promoter. To iden-
tify the contribution of each one of these three sites, we elimi-
nated their binding capacity by changing key nucleotides from
their consensus sequences.Mutation of Egr1 did notmodify the
levels of luciferase activity (Fig. 4D). However, the capacity of
the promoter to induce luciferase was significantly reduced fol-
lowing mutation of p53 (about 12-fold reduction) and Sp1
(about 3-fold reduction) binding sites.
p73 and Sp1 Play Key Roles in the Cisplatin-induced Up-reg-
ulation of Noxa—To further explore the contribution of each
transcription factor to the induction of Noxa under apoptosis-
inducing conditions, we inhibited the expression of p53 or Sp1
in NTERA2 cells by using interference RNAs and determined
the expression of Noxa protein in response to cisplatin. p53,
which has been shown to promote the expression of Noxa in
different cell systems (10), was clearly induced in control cells
but not in cells transfected with a p53-specific shRNA (Fig. 5A).
Surprisingly, the levels of Noxa were very similar in both cell
populations following exposure to the drug. However, consis-
tent with the apoptotic role of p53, cells defective in this tran-
scription factor were less responsive to cisplatin (cell death
decreased from 61% in control cells to 37% in p53-defective
cells) (Fig. 5B), which suggests that p53 may contribute to apo-
ptotic cell death through Noxa-independent mechanisms.
Another p53 family member, p73, shares a remarkable homol-
ogy in the sequence-specific DNA binding domain with p53
(29) and is able to bind to p53 consensus sites and to activate
p53 target genes. ChIP analyses demonstrated the binding of
p73 to the corresponding site in the Noxa promoter, which was
further enhanced (about 3-fold increase) in the presence of cis-
FIGURE 1. Noxa expression in germ cell tumor cell lines. The expression
levels of the indicated Bcl-2 family members were determined by A, Western
blot analysis and B, quantitative RT-PCR. C. Cell extracts from NTERA2 were
analyzed by immunoprecipitation (IP) with antibodies against Mcl-1 at two
different concentrations, andby subsequentblottingwith antibodies specific
for Mcl-1, Noxa, and Bad. Histograms represent the mean  S.D. of three
independent experiments.
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platin (Fig. 5C). The protein levels of both, transcriptionally
active (TA) and dominant negative (N) isoforms of p73 were
either unchanged or slightly down-regulated following treat-
ment with cisplatin (Fig. 5A). To study the contribution of p73
in this transcriptional system, cells were transfected with
TAp73 or the truncated isoform, Np73. Overexpression of
TAp73 induced Noxa protein, whereas functional blockade of
p73 reduced the expression of Noxa (Fig. 5D). Moreover,
TAp73 promoted an increase (about 2-fold) in luciferase activ-
ity when this factor was cotransfected with a Noxa promoter-
luciferase reporter construct into p53-defective NTERA2 cells.
On the contrary, Np73 caused a 4-fold reduction in luciferase
activity (Fig. 5E). Consistent with these results,Np73 reduced
cisplatin-induced cell death from 42% in control cells to 17% in
Np73-tranfected cells (Fig. 5F), and decreased the upregula-
tioin of Noxa mRNA levels in response to cisplatin (Fig. 5G). In
order to confirm these data in another embryonal carcinoma
cell line, we transfected 2102Ep cells with Np73 and found
that these cells also had a reduced capacity to up-regulate Noxa
(Fig. 5H) and to undergo apoptosis (data not shown) following
FIGURE2.1411HPcells are resistant to cisplatin.A, TGCTcell lineswere treatedwith12Mcisplatin for 24hand thencell deathwasdeterminedbycytometry
using TUNEL assay. Percentages of apoptosis are indicated. B, cisplatin-induced apoptosis was also determined by Western blot analysis of PARP cleavage at
24 h or at the indicated time points. C, NTERA2 and 1411HP cells were treatedwith cisplatin and the protein expression of Noxawas analyzed byWestern blot.
The levels of -tubulin were also analyzed to assure equal loading.D, NTERA2 and 1411HPwere transfected with a luciferase reporter plasmid containing the
Noxa promoter. Following treatment with cisplatin, cell extracts were analyzed for the relative luciferase activity. Histograms represent the mean  S.D. of
three independent experiments.
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treatment with cisplatin. These data indicate a direct participa-
tion of p73 in the expression of Noxa and therefore, in the
response of NTERA2 cells to cisplatin.
Next, we knocked down Sp1 transcription factor (Fig. 6A).
Specific shRNAs virtually eliminated the expression of Sp1 but
not of other member of the same protein family, KLF6. Unex-
pectedly, Noxa protein levels were increased. Consistent with
this result, Sp1 deficiency caused a 5-fold increase in luciferase
activity in cells cotransfected with the Noxa promoter-reporter
construct (Fig. 6B), and induced a higher cell death response to
cisplatin (mean of 80%) as comparedwith control cells (mean of
56%) (Fig. 6C). Moreover, the binding of Sp1 to its correspond-
ing site in the Noxa promoter was reduced following cisplatin
exposure as determined by EMSA (Fig. 6D), which correlates
with a decrease in the protein levels of Sp1, but not of KLF6 (Fig.
6E). ChIP analyses of NTERA2 cells also revealed a decrease of
Sp1 binding to the corresponding site in the Noxa promoter
following treatment with cisplatin (Fig. 6F). Interestingly,
KLF6, that has been reported as a candidate tumor suppressor
gene in different cell systems, binds to the same site in theNoxa
promoter and this binding increased in response to cisplatin
(Fig. 6F). These data suggest a competition between Sp1 and
KLF6 for binding to Noxa promoter.
The Balance between KLF6 and Sp1 Determines the Tran-
scriptional Control of Noxa—Sp1 belongs to a complex family
of transcriptional regulators that includemore than 20 Sp1-like
proteins and Kruppel-like factors (KLF), and competition for
DNA binding has been shown for different family members
(30). Protein analysis showed that exogenous KLF6 failed to
modify Noxa levels in wild type NTERA2 cells. However, in the
absence of Sp1, KLF6 increased the expression of Noxa (Fig.
7A). The capacity of KLF6 to transactivate the Noxa promoter
was first analyzed inDrosophila Schneider cells, which lack Sp1
and KLF6 (25). In these cells, exogenous KLF6 was able to
induce expression of a luciferase gene driven by the Noxa pro-
moter, in a dose-dependent manner (Fig. 7B). Moreover, KLF6
overexpression induced a slight increase (about 1.5-fold) in the
activity of the Noxa promoter-luciferase construct in NTERA2
cells, but promoted a stronger activation of luciferase (about
4-fold) in cells lacking Sp1. However, overexpression of a trans-
activation defective variant of KLF6, Sv2, did not have any sig-
nificant effect on theNoxa promoter activity (Fig. 7C). To study
whetherKLF6wasmediating at least in part, the transactivation
of the Noxa promoter in response to cisplatin, we took advan-
tage of the capacity of Sv2 to inhibit the binding of functionally
competent KLF6. Luciferase assays showed that the alterna-
tively spliced variant of KLF6 induced an average of 40% reduc-
tion in the activity of the Noxa promoter following treatment
with cisplatin (Fig. 7D), and consistently Sv2 decreased the cis-
platin-induced up-regulation of Noxa mRNA levels in both
NTERA2 (Fig. 7E) and 2102EP (Fig. 7F) cell lines. Thus, KLF6
promotes the transcriptional activation of Noxa in response to
chemotherapy in embryonal carcinoma cells, and its relative
contribution depends on the endogenous levels of Sp1, which is
acting as a transcriptional repressor of Noxa in these tumor
cells.
Noxa Protein Levels Correlate with Clinical Prognosis—To
translate our previous data to a clinically relevant setting, we
analyzed the expression levels of Noxa in 436 tissue sections
from tumors of different histological types, including semi-
noma (18.2%), embryonal carcinoma (36%), teratoma (17.2%),
yolk sac tumor (15.3%), and choriocarcinoma (13.3%) in tissue
microarrays. We considered good, intermediate and bad prog-
nostic groups, as classified by the International GermCell Can-
cer Collaborative Group (26). We also included a group of
patients refractory to cisplatin-based chemotherapy, which
have a poor prognosis. Clearly visible differences in Noxa
expression were observed between tissue sections within the
same histological type (Fig. 8, A and B). Notably, significant
differences in the protein levels ofNoxa between the prognostic
groups were only observed in embryonal carcinoma, the same
histological type as NTERA2. In this tumor, we found higher
levels ofNoxa in diseasewith good prognostic criteria (81 tissue
sections) as compared with intermediate (p 0.0001) and bad
(p  0.001) prognosis disease (16 and 25 tissue sections ana-
lyzed, respectively) (Fig. 8C). Comparison between the good
prognostic group and the group of patients with refractory dis-
ease (35 sections) showed no significant difference (Fig. 8C),
suggesting that alternative apoptosis regulatory pathways
might be active in tumor cells refractory to chemotherapy.
Overall, the extent and intensity of embryonal carcinoma tissue
staining with Noxa was statistically decreased in cases with
intermediate or low response to cisplatin-based chemotherapy.
DISCUSSION
It is well established that certain cancers, including testicular
carcinoma, Wilms tumor, and pediatric Hodgkin disease, are
FIGURE 3. Down-regulation of Noxa reduces the sensitivity of NTERA2
cells to cisplatin. A, NTERA2 cells were transfected with different shRNA-
containing plasmids specific for Noxa and the levels of the targeted protein
were analyzed by Western blot. B, participation of Noxa in TGCT cell chemo-
sensitivity was determined by comparing viabilities of Noxa knockdown cells
(sh2) and mock-transfected cells (C) after treatment with cisplatin. 1411HP
cells were included as a control of chemoresistance. Cell viability was ana-
lyzed by using the WST-1 reagent. Asterisk represents significant differences
(p  0.001). Histograms represent the mean  S.D. of three independent
experiments.
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FIGURE4.Sp1andp53sites in theNoxapromoter arenecessary for transactivation inTGCTcells.A, schemeof theNoxapromoter showing the consensus
sites for different transcription factors. Numbering starts at the first nucleotide upstream from the transcription start site (TSS). B and C, NTERA2 and 2102Ep
cells were transfected with a luciferase reporter vector containing sequential deletion fragments of the Noxa promoter. Following 24 h of transfection, cell
extractswere prepared and analyzed for the relative luciferase activity.D, reporter vector containingmutant Egr1, p53, or Sp1 sitewas introduced intoNTERA2
cells and luciferase activity was determined. Results were normalized for transfection efficiency with values obtained with pRSV--gal. Histograms represent
the mean S.D. of three independent experiments.
FIGURE 5. Cisplatin-induced expression of Noxa is dependent on p73 but not p53 in embryonal carcinoma cells.NTERA2 cells transfected with a vector
expressing a shRNA targeted against p53 were treated with cisplatin and A, the expression levels of Noxa, p53 and p73 isoforms were determined byWestern
blot analysis, and B, cell death was determined following 24 h of treatment. C, ChIP analysis of the association of p73 with the Noxa promoter in the presence
or in the absence of cisplatin. Immunoprecipitates were analyzed by quantitative PCR using primers specific to the target site or a 3 kb upstream region. Fold
enrichment is expressed relative to IgG immunoprecipitates. D, protein levels of Noxa were analyzed in NTERA2 cells overexpressing an active (TA) or a
dominant negative form (N) of p73. Sampleswere runon the samegel but not in consecutive lanes. The levels of-tubulinwere also analyzed to assure equal
loading. E, p53 knockdown cells were transfectedwith TAp73 orNp73 and a luciferase-Noxa promoter vector and then analyzed for luciferase activity. F, p53
knockdown cells transfected with Np73 were treated with cisplatin and 24 h later cell death was quantified. G, p53 knockdown NTERA, and H, 2102EP cells
were transfected withNp73 and treated with cisplatin for 24 h. ThemRNA levels of Noxa were determined by quantitative RT-PCR. *, p 0.01; **, p 0.001.
Histograms represent the mean S.D. of three independent experiments.
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chemosensitive (31–33), evenwith drugs that show low efficacy
in other tumors. However, there is little understanding of the
underlying mechanisms that might explain why these cancers
respond so well to chemotherapy. The National Cancer Insti-
tute has identified this issue as one of the provocative questions
that need to be addressed to drive progress against cancer (34).
Thus, unraveling the properties of cancers that render them
susceptible to eradication by chemotherapy, might help under-
stand how certain therapies work, or develop new approaches
to treat chemoresistant tumors.We have focused on TGCTs as
a model of chemosensitivity to cisplatin-based therapies. Cis-
platin is a genotoxic agent and the p53 pathway is known to
participate in regulating the cellular response to this drug.
Using TGCT cell lines, we found a much higher basal expres-
sion of Noxa in cisplatin-sensitive cells (NTERA2, 2102Ep)
than in chemoresistant cells (1411HP). Furthermore, cisplatin-
induced apoptosis increased the levels of Noxa in chemosensi-
tive cell lines, which is consistent with the strong up-regulation
of Noxa by platinum compounds described in other cell models
(35). Down-regulation of Noxa by interference strategies
reverted the sensitivity to cisplatin indicating that this proapo-
ptotic BH3-only protein plays a key role in the cellular response
to cisplatin in TGCT cells. Although cisplatin is widely used to
treat different tumors, induction of Noxa by this drug has not
been observed in other tumor models such as non-small cell
lung cancer cells (36). Other proapoptotic members of the
BH3-only family, including Puma and Bim, have been associ-
ated with the apoptotic response to cisplatin (37, 38), which
exemplifies the redundancy of this family of apoptosis regula-
tors. To further understand the mechanisms that control the
expression levels of Noxa in TGCT cells, we analyzed in detail
the promoter of this gene and found that p53 and Sp1 sites but
not HIF1, Egr1, or E2F1 are essential for the transcriptional
activity of the promoter. Interestingly, induction of Noxa was
dependent on p73 but not p53, which is consistent with the
observation that Noxa induction is key in determining apopto-
sis of different tumor cells in a p53-independent manner (20,
39). Although recent data suggested that p53 plays a major role
in Noxa expression and the chemotherapeutic response of
TGCT cell lines (21), other authors have showed that the
unique sensitivity of TGCT cells to cisplatin could be attributed
to p53-dependent and p53-independent pathways (40, 41).
Even though, it is likely that the cellular context or clonal dif-
ferences in the expression levels or activity of p53 and p73,
which bind to the same response elements, may determine the
contribution of each one to the activation of a target gene. In
FIGURE 6.Sp1 is blocking the expressionofNoxa.A, NTERA2 cellswere transfectedwith shRNAs specific for Sp1 and theprotein levels of Noxa, Sp1 andKLF6
were determined byWestern blot. The levels of-tubulinwere also analyzed to assure equal loading. B, NTERA2 cells lacking Sp1were transfectedwith aNoxa
promoter-luciferase reporter vector. Following 24 h of transfection, cell extracts were analyzed for the relative luciferase activity. C, Sp1-deficient NTERA2 cells
were treated with cisplatin and cell death was quantified 24 h later. C, cells transfected with an irrelevant shRNA-containing plasmid. *, p 0.02; **, p 0.001.
D, NTERA2 cellswere treatedwith cisplatin and the formationof protein-DNAbinding complexeswas analyzedby EMSA. Antibodies against Sp1 and irrelevant
GATA1 were used for supershift. Arrowheads indicate the specific bands. E, proteins levels of Noxa, Sp1, and KLF6, with or without cisplatin exposure were
determined byWestern blotting. F, a ChIP assay was performed to study the in vivo binding of Sp1 and KLF6 to the promoter of Noxa in response to cisplatin.
Cross-linked chromatin was incubated with the indicated antibodies. Immunoprecipitates were analyzed by quantitative PCR using primers specific to the
target site or a 3 kb upstream region. Fold enrichment is expressed relative to IgG immunoprecipitates. Histograms represent the mean  S.D. of three
independent experiments. *, p 0.05.
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line with this, it has been proposed that regulation of p53 family
protein activity depends on the relative expression of transcrip-
tionally active proteins and inactive isoforms (42). An alterna-
tive explanation may reside in clonal differences in the expres-
sion of genes that could promote some degree of spontaneous
differentiation (43), as short-term differentiation of NTERA2
cells causes a loss in p53-dependent hypersensitivity (21). In
addition to p73, we found that the Sp1 site in the Noxa pro-
moter participates in the transcriptional control of this gene. It
has been shown that the apoptotic activity of butyrate in colon
cancer cells requires a reduction of the Sp1 binding to its con-
sensus site in the Bak promoter in favor of Sp3 binding (44). In
NTERA2 cells, we found that knockdownof Sp1 correlateswith
up-regulation of Noxa and a stronger response to cisplatin, and
that another member of the Sp1-like family, KLF6, is able to
transactivate Noxa in competition with Sp1. Consistent with
this, competition for DNA binding has been shown for some
members of the family; for example, Sp1 competes with KLF4,
KLF9, andKLF13 (30).Moreover, Sp1 and p73 appears to coop-
eratively activate apoptotic genes such as Puma, and caspase-3
(45, 46). However, we demonstrate that Sp1 may exert a tran-
scriptional suppression of a gene involved in the apoptotic
response to chemotherapeutic drugs. Accumulating evidence
suggests that the tumor suppressor gene KLF6 and its domi-
nant-negative splicing variants play important roles in the
FIGURE 7.KLF6 is a transcriptional activator of Noxa inNTERA2 cells. A, wild type and Sp1-deficient cells were transfectedwith KLF6 and the levels of Noxa
protein were analyzed. The expression of -tubulin was also analyzed to assure equal loading. B,Drosophila Schneider cells were cotransfected with the Noxa
promoter-luciferase construct and increasing amounts of a KLF6-containing plasmid and then, luciferase activity was determined. C, NTERA2 cells were
transfected with the Noxa promoter-luciferase construct and the indicated plasmids, and the promoter activation was determined by analyzing luciferase
activity.D, NTERA2 cells cotransfectedwith theNoxa promoter and Sv2 in the presence or in the absence of cisplatin. After 3 h of treatment luciferase activity
was analyzed. E, NTERA2 and F, 2102Ep cells were cotransfected with the Noxa promoter and Sv2. The levels of NoxamRNA in response to cisplatin were
determined by quantitative RT-PCR. Asterisk, significant differences (p  0.01). Histograms represent the mean  S.D. of three independent
experiments.
FIGURE 8. Noxa expression correlates with response to cisplatin-based
chemotherapy in embryonal carcinoma. A and B, representative examples
of negative and intensively positive staining for Noxa in embryonal carci-
noma components of TGCT patients on a tissue microarray. C, quantifica-
tion of Noxa levels in tumor tissue sections from patients with good (GP),
intermediate (IP), or bad (BP) prognosis. RF, patients refractory to
chemotherapy.
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development and/or progression of cancer (47). A recent work
described that a splice variant of KLF6, KLF6-SV1, targetsNoxa
for degradation in cancer cell lines (48). SV1 antagonizes wild
type KLF6 function and may be acting as a tumor promoter
gene (49). Therefore, we provide the first description of a com-
petitive transcription factor bindingmechanism formed by Sp1
andKLF6 that control a proapoptoticmember of the Bcl-2 fam-
ily. Finally, we showed for the first time that Noxa positivity of
embryonal carcinoma components in TGCT tissue specimens
correlated with a good response to cisplatin-containing chem-
otherapy. This result is consistent with our in vitro data in
which Noxa induction plays a key role in determining the apo-
ptotic response to cisplatin. However, no correlation was
observed in a group of patients refractory to treatment, most
likely due to activation of alternative pathways regulating apo-
ptosis. In line with this, it has been recently described that cis-
platin-resistance in testicular embryonal carcinoma cells corre-
lates with high amounts of cytoplasmic p21, resulting in CDK2
inhibition and reduced levels of cisplatin-induced apoptosis
(50). In conclusion, we demonstrate the relevance of a tran-
scriptional network formed by p73 isoforms, Sp1, and KLF6 in
the regulation of Noxa levels in TGCT cells, which mediates
their apoptotic response to cisplatin. Moreover, immunoreac-
tivity for Noxa in the embryonal carcinoma component was
more often observed in good prognostic patients, thus provid-
ing a predictive marker of therapeutic response.
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